Skin2Neuron

Executive Summary

Skin2Neuron (S2N) is an Australian preclinical biotech developing autologous, gene-modification-free neuronal cell therapies from hair follicle-derived neuroprecursors (HFN). Their platform generates pure neurons for regenerative treatment of Alzheimer's dementia and other neurodegenerative disorders. Founded in 2019 and headquartered in Sydney, S2N has raised $4.4M and employs 10-50 staff. The company's approach avoids ethical and immune rejection issues associated with embryonic or allogeneic cells, leveraging patients' own hair follicles to produce neurons that could integrate into damaged brain tissue. Given the vast unmet need in Alzheimer's and Parkinson's diseases, S2N's technology offers a potentially scalable and personalized therapeutic solution. However, the company remains at preclinical stage, and significant clinical validation, manufacturing scale-up, and funding are required to advance towards human trials.

Upcoming Catalysts (preview)

• Q3 2026Preclinical efficacy data in animal models of Alzheimer's disease60% success
• H2 2026Series A financing round to support IND-enabling studies40% success
• H1 2027Partnership or licensing deal with a larger pharma or cell therapy company30% success